In Diastolic Heart Failure Anakinra Response Trial 2 (D-HART 2), IL-1 blockade by anakinra, a recombinant IL-1 receptor antagonist, reduced CRP (C-reactive protein) and NT-proBNP plasma levels in HFpEF patients after 12 weeks of treatment (Van Tassell et al., 2018), however it failed to improve aerobic exercise capacity or ventilation efficiency (Van Tassell et al., 2018). This evidence concerns the gene CRP and diastolic heart failure.